印度制药公司 Eris Lifesciences 以 63.75 亿卢比（7,670 万美元）收购 Swiss Parenterals 51% 的股份，扩大出口市场，利用瑞士的优势 Indian pharma firm Eris Lifesciences acquires 51% stake in Swiss Parenterals for Rs 637.5 crore ($76.7m), expanding export market, leveraging Swiss'
印度制药公司 Eris Lifesciences 以约 63.75 亿卢比（7,670 万美元）收购了无菌注射剂公司 Swiss Parenterals 51% 的股份。 Eris Lifesciences, an Indian pharmaceutical company, has acquired a 51% stake in Swiss Parenterals, a sterile injectables firm, for approximately Rs 637.5 crore ($76.7 million). 该交易旨在加强 Eris 在印度的业务，扩大其出口市场，并利用瑞士的海外分销渠道和监管专业知识。 The deal aims to strengthen Eris' India footprint, expand its export market, and leverage Swiss' overseas distribution channels and regulatory expertise. Swiss Parenterals 在非洲、亚太地区和拉丁美洲的新兴市场拥有强大的影响力，补充了 Eris 对印度的关注。 Swiss Parenterals has a strong presence in emerging markets across Africa, Asia Pacific, and Latin America, complementing Eris' focus on India.